TrialNature communications2022

A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.

Nan Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.